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Abstract 
Background: In this study, our aim was to identify Candida species isolated from bloodstream infections and to 
determine their susceptibilities to various antifungal agents to demonstrate the local resistance profiles and to guide 
empirical treatment for clinicians.
Methods: Two hundred Candida isolates (95 Candida albicans, 105 non-albicans Candida strains) were included in 
the study. Candida species were identified by conventional, biochemical and molecular methods. Antifungal sus-
ceptibility tests for amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin and anidulafungin were 
performed with broth microdilution method according to the Clinical and Laboratory Standards Institute M27-A3 
document.
Results: Of the 200 Candida strains, the most prevalent species were C. albicans (47.5 %), Candida glabrata (18.0 %) 
and Candida parapsilosis complex (14.0 %). All Candida species except for three (1.5 %) Candida kefyr strains were sus-
ceptible to amphotericin B. Only one (2.8 %) C. glabrata was resistant to fluconazole (MIC ≥ 64 μg/ml), and the others 
(97.2 %) exhibited dose-dependent susceptibility. All species, but C. glabrata strains, were susceptible to fluconazole. 
Resistance to voriconazole, posaconazole, caspofungin and anidulafungin was not detected in any strain.
Conclusion: Candida albicans were susceptible to all antifungal drugs. Three C. kefyr strains were resistant to ampho-
tericin B. Only one C. glabrata was resistant to fluconazole. All the strains were susceptible to voriconazole, posacona-
zole, caspofungin and anidulafungin. In vitro antifungal susceptibility tests should be performed to select of appropri-
ate and effective antifungal therapy, and monitor the development of resistance.
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Background
Candida species are common in nature and the flora 
of the human skin and mucosa and have been reported 
more frequently as pathogens. This is because of the risk 
factors such as increased use of broad-spectrum antibi-
otics, underlying malignant diseases, HIV/AIDS, organ 
transplantation, prolonged hospital stay, and exposure to 
invasive procedures, various opportunistic fungal infec-
tions have increased [1, 2].
Candida species can lead to a wide range of serious 
infections including blood stream infections (BSIs) and 
disseminated candidiasis. Candida species are fourth 
most frequent pathogens in BSIs. In spite of the advances 
in the diagnosis and treatment of candidiasis, the infec-
tions still have high mortality rates [3, 4].
In recent years, a gradual increase in the fungal diseases 
and the widespread use of empirical antifungals caused 
the emergence of resistant strains of fungi. Therefore, 
in vitro antifungal susceptibility testing requirements are 
increasing to select appropriate and effective antifungal 
therapy. The main purpose for using these tests to enable 
to anticipate the clinical success during the treatment of 
infections [5].
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Antifungal susceptibility tests provide useful informa-
tion to the clinicians about empirical treatments. There 
are some studies on the antifungal susceptibility of Can-
dida species with broth microdilution method from 
Turkey [6–8], but there is no published research evalu-
ated according to species-specific clinical breakpoints in 
the Clinical and Laboratory Standards Institute (CLSI) 
M27-S4 document. In this study, our aim was to iden-
tify Candida species isolated from BSIs and to deter-
mine the susceptibility to various antifungals including 
amphotericin B, fluconazole, voriconazole, posaconazole, 
caspofungin, and anidulafungin to demonstrate the local 
resistance profiles and to guide empirical treatment for 
clinicians.
Methods
This study was approved by Ethical Committee of Faculty 
of Medicine, Selcuk University (2011, 13).
A total of 200 Candida isolates (Candida albicans: 93, 
Candida glabrata: 36, Candida parapsilosis complex: 28, 
Candida tropicalis: 24, Candida kefyr: 10, Candida lusi-
taniae: 7, and Candida dubliniensis: 2) were collected 
between 2010 and 2013 from blood cultures of hospital-
ized patients in various departments of the Selcuk Uni-
versity, Faculty of Medicine. Candida strains isolated 
from the clinical samples were identified by conventional 
methods (germ tube test, morphology on corn meal agar) 
and API ID 32C (bioMerieux, France) according to the 
manufacturer’s instructions. The isolates were stored at 
−70 °C in the Brain Heart Infusion broth (Oxoid, United 
Kingdom) with 20 % glycerol until they were studied.
After the stored isolates were subcultured, DNA was 
extracted using a commercial DNA isolation kit (Gentra 
Puregene Yeast/Bact. Kit, Qiagen, Valencia, CA, USA) 
according to the manufacturer’s recommendations. The 
primers (CR-f 5′-GCTACCACTTCAGAATCATCATC-3′ 
and CR-r 5′-GCACCTTCAGTCGTAGAGACG-3′) 
encoding hypha l wall protein 1 (HWP1) gene were 
selected to identify C. albicans and C. dubliniensis cor-
rectly. The PCR conditions were performed as described 
before [9]. PCR amplification products were electro-
phoresed on 1.3  % (wt/vol) agarose gel and visualized 
by staining with ethidium bromide (0.5  µg/mL) using a 
GelDoc imaging system (BioRad, Hercules, CA, USA). 
The isolates yielded a DNA fragment of 1000  bp were 
identified as C. albicans. The molecular identification 
of C. parapsilosis complex was performed by sequenc-
ing the internal transcribed spacer (ITS) region with 
ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 
(5′-TCTTTTCCTCCGCTTATTGATATG-3′) primers 
as previously described [10]. The amplicons were puri-
fied with commercial kit (QIAquick PCR Purification Kit, 
Qiagen, Valencia, CA, USA) and were analyzed by the 
use of an ABI 3100 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA, USA). The sequences were evalu-
ated using the Sequencer 5.3 software and compared 
with GenBank.
Antifungal susceptibility tests were performed by broth 
microdilution method as described in the CLSI M27-
A3 document [11]. The following antifungals were used: 
amphotericin B, fluconazole, voriconazole, posaconazole, 
caspofungin (Sigma-Aldrich, St. Louis, MO, USA) and 
anidulafungin (Pfizer, New York, NY, USA). The antifun-
gal agents and concentration ranges were between 0.015 
and 16 µg/mL for amphotericin B, voriconazole and posa-
conazole; 0.12–64  µg/mL for fluconazole; 0.008–8  µg/
mL for anidulafungin and caspofungin. The minimum 
inhibitory concentration (MIC) values for all agents were 
read following 24 h of incubation at 35 °C. The MIC val-
ues were visually determined at the lowest concentration 
of drug that prevents any noticeable growth for ampho-
tericin B and a significant reduction of growth (≥50  %) 
for the azoles and the echinocandins compared with the 
drug-free growth control. Species-specific clinical break-
points in the M27-S4 document were used for categorical 
evaluation [12]. Due to the lack of published breakpoints 
by CLSI for posaconazole, the voriconazole breakpoints 
were used for posaconazole. The isolates had ≤1 µg/mL 
MIC for AmB were accepted susceptible according to 
CLSI M27-S3 [13]. C. parapsilosis ATCC 22019 and C. 
krusei ATCC 6258 were used as quality control strains.
Results
A total of 93 C. albicans and two C. dubliniensis isolates 
were identified as C. albicans by HWP1 gene polymor-
phisms. The 28 C. parapsilosis complex isolates were 
sequenced, and all of the strains were identified as C. par-
apsilosis. None of the C. parapsilosis complex strains was 
identified Candida metapsilosis or Candida orthopsilosis.
Antifungal susceptibility results and MIC values as well 
as categories of the isolates were presented in Table  1. 
All Candida species except for C. kefyr were susceptible 
to amphotericin B. MIC values of three C. kefyr strains 
were 2  µg/mL for AmB. AmB had the lowest MIC90 
value (0.25  µg/mL) against C. albicans and C. parap-
silosis. Only one C. glabrata strain was resistant to flu-
conazole (MIC  =  ≥64  μg/mL), and the others showed 
dose-dependent susceptibility. The other Candida spe-
cies were susceptible to fluconazole. All strains were sus-
ceptible to voriconazole, posaconazole, caspofungin and 
anidulafungin. Voriconazole and posaconazole had the 
same MIC90 value (0.06  µg/mL), but posaconazole had 
the lower MIC50 value (≤0.015  µg/mL) than voricona-
zole (0.03 µg/mL). By having MIC90 values of 0.06 µg/mL, 
caspofungin and anidulafungin were potentially active 
agents against Candida species.
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 Amphotericin B 0.06–2.0 0.12 0.5 100 – 0
 Fluconazole 0.12– ≥ 64.0 0.25 1.0 – – –
 Voriconazole ≤0.015–0.12 0.03 0.06 – – –
 Posaconazole ≤0.015–0.12 ≤0.015 0.06 – – –
 Caspofungin ≤0.008–0.12 0.015 0.06 – – –
 Anidulafungin ≤0.008–0.12 0.03 0.06 – – –
C. albicans (95)
 Amphotericin B 0.12–1.0 0.12 0.25 100 – 0
 Fluconazole 0.12–2.0 0.25 0.5 100 0 0
 Voriconazole ≤0.015–0.06 ≤0.015 0.03 100 0 0
 Posaconazole ≤0.015–0.12 ≤0.015 0.03 100 0 0
 Caspofungin ≤0.008–0.12 0.015 0.06 100 0 0
 Anidulafungin 0.015–0.12 0.015 0.03 100 0 0
C. glabrata (36)
 Amphotericin B 0.06–1.0 0.12 0.5 100 – 0
 Fluconazole 0.12– ≥ 64.0 1.0 4.0 – 97.2 2.8
 Voriconazole ≤0.015–0.12 0.03 0.06 – – –
 Posaconazole ≤0.015–0.12 0.06 0.12 – – –
 Caspofungin ≤0.008–0.12 0.06 0.12 100 0 0
 Anidulafungin 0.015–0.12 0.03 0.06 100 0 0
C. parapsilosis (28)
 Amphotericin B 0.06–0.5 0.12 0.25 100 – 0
 Fluconazole 0.12–0.5 0.12 0.5 100 0 0
 Voriconazole ≤0.015–0.03 ≤0.015 0.03 100 0 0
 Posaconazole ≤0.015–0.03 ≤0.015 0.03 100 0 0
 Caspofungin 0.015–0.12 0.015 0.06 100 0 0
 Anidulafungin 0.015–0.12 0.015 0.06 100 0 0
C. tropicalis (24)
 Amphotericin B 0.12–0.5 0.25 0.5 100 – 0
 Fluconazole 0.12–1.0 0.25 1.0 100 0 0
 Voriconazole ≤0.015–0.06 0.03 0.06 100 0 0
 Posaconazole ≤0.015–0.03 ≤0.015 0.03 100 0 0
 Caspofungin ≤0.008–0.06 0.015 0.06 100 0 0
 Anidulafungin 0.015–0.06 0.03 0.06 100 0 0
C. kefyr (10)
 Amphotericin B 0.12–2.0 0.5 2.0 70 0 30
 Fluconazole 0.12–0.5 0.25 0.25 – – –
 Voriconazole ≤0.015–0.03 ≤0.015 0.03 – – –
 Posaconazole ≤0.015–0.03 ≤0.015 0.03 – – –
 Caspofungin ≤0.008–0.03 0.015 0.03 – – –
 Anidulafungin 0.015–0.12 0.03 0.06 – – –
C. lusitaniaea (7)
 Amphotericin B 0.12–0.25 – – –
 Fluconazole 0.12–1.0 – – –
 Voriconazole ≤0.015–0.6 – – –
 Posaconazole ≤0.015–0.6 – – –
 Caspofungin ≤0.008–0.03 – – –
 Anidulafungin 0.015–0.06 – – –
S susceptible; S-DD susceptible-dose dependent; I intermediate; R resistant
a A categorical evaluation was not performed because the number is smaller than ten
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Discussion
The surveillance programs have performed invasive 
Candida infections and investigated the distribution 
of species and antifungal susceptibility. In this study, 
we identified Candida species isolated from BSIs and 
determined their susceptibilities to amphotericin B, flu-
conazole, voriconazole, posaconazole, caspofungin, and 
anidulafungin using species-specific clinical breakpoints 
in the M27-S4 document.
Candida albicans is responsible for about 50  % of sys-
temic infections caused by Candida species, making it 
the most common infectious Candida agent [14–16]. 
The changes in the distribution of Candida species have 
been observed and the rates of non-albicans species such 
as C. glabrata, C. tropicalis and C. parapsilosis have been 
increasingly reported. C. albicans still is the most common 
agent in many studies although its proportion significantly 
decreased from 64 to 45 % in Asia–Pacific and from 68 to 
50 % in Europe recently [16, 17]. Even the distribution of 
some species shows variation in different regions of the 
same country. In a study from Italy, C. parapsilosis was 
higher in the center and in south than the north (25.7 vs. 
19.9  %). In addition, C. glabrata was higher in the south 
than in any other region (7.5 vs. 15.9 %) [18]. In this study, 
the prevalence was as follows: C. albicans, (47.5  %) C. 
glabrata (18.0  %), C. parapsilosis (14.0  %), C. tropicalis 
(12.0 %), C. kefyr (5.0 %) and C. lusitaniae (3.5 %). Previous 
studies reported C. albicans is the most common agent of 
candidemia in Turkey [6, 7, 19], except one study reported 
that C. parapsilosis was the most common pathogen at the 
rate of 55.4 % in blood cultures in İzmir [20].
In recent years, the low rates of amphotericin B resist-
ance have been reported in the C. albicans, C. glabrata, 
C. parapsilosis, C. tropicalis, C. kefyr and C. krusei iso-
lates [7, 21, 22]. However, in a study conducted by Ruan 
et  al. [23], the resistance was extremely high against 
amphotericin B in C. krusei strains (95  %) and in C. 
glabrata strains (53  %). In our study, all strains except 
for C. kefyr had MICs of ≤1 µg/mL for amphotericin B. 
Amphotericin B has had the lowest MIC90 value (0.25 µg/
mL) against C. albicans and C. parapsilosis. In previous 
studies from Turkey, amphotericin B resistance rates 
ranged from 0 to 3.8 % [6, 7, 24], which was compatible 
(1.5 %) with this study.
Although, fluconazole is most frequently used an agent 
in the treatment of systemic yeast infections, resistance 
rates have been reported for C. albicans (5.7–5.8 %) and 
for C. tropicalis (6.2–9.8 %) [25–27]. Globally, C. glabrata 
showed the higher resistant rates (7.7–11.9 %) than other 
Candida species [16, 27–29]. In Turkey, resistance rates 
to fluconazole is low [6, 8], but the higher resistant rate 
(12.8  %) in C. glabrata was reported by another study 
[24]. In our study, one C. glabrata strain was resistant to 
fluconazole, the other strains (97 %) were dose-depend-
ent susceptible. Other Candida species were susceptible 
to fluconazole.
Because of a high in  vitro activity, voriconazole and 
posaconazole are more successful choices in the treatment 
of fluconazole-resistant Candida species [30]. Among 
Candida species, alike to fluconazole, C. glabrata had the 
highest MIC90 values for voriconazole and posaconazole 
[27, 29]. However in another study the highest resistance 
rates to voriconazole were determined in C. tropicalis 
(17.6 %), following C. krusei (7.1 %) and C. albicans (4.6 %) 
[25]. In our study, voriconazole and posaconazole had the 
same MIC90 value (0.06  µg/mL), but posaconazole had 
the lower MIC50 value (≤0.015 µg/mL) than voriconazole 
(0.03 µg/mL). The highest MIC values (0.12 µg/mL) were 
detected in C. glabrata isolates. All Candida species were 
susceptible to voriconazole and posaconazole. Moreover, 
so far, no voriconazole resistance has been reported from 
Turkey [6–8].
So far, although species-dependent resistance was 
undetermined, resistance to echinocandins in Can-
dida species has been reported in some publications 
[28, 29, 31]. Resistance to caspofungin in C. albicans 
(0.2–0.5  %), in C. parapsilosis (1.9  %), in C. tropica-
lis (0.8 %) were low rates [27, 29]. However, the higher 
resistance rates to caspofungin between 5.1 and 7.9 % in 
C. glabrata have been reported [28, 29]. Insomuch that, 
C. glabrata isolates were resistant to caspofungin at 
rate of 100 %, but susceptible to anidulafungin [21]. In 
this study, caspofungin and anidulafungin were poten-
tially active against Candida species with MIC90 values 
0.06  µg/mL, and no resistant strain was detected. In 
Turkey, caspofungin resistance was reported in 14 C. 
parapsilosis isolates [8].
Conclusion
Candida albicans were susceptible to all antifungal 
drugs. Three C. kefyr strains were resistant to ampho-
tericin B. Only one C. glabrata was resistant to flucona-
zole. All the strains were susceptible to voriconazole, 
posaconazole, caspofungin and anidulafungin. Accord-
ing to our test results, there is no remarkable antifungal 
resistance in our hospital. Therefore, Candida isolates 
should be identified at the species level and MIC values 
should be determined even though very little resistance 
was detected. This study is the first investigation using 
species-specific clinical breakpoints in the M27-S4 docu-
ment for categorical evaluation in Turkey. In  vitro anti-
fungal susceptibility tests should be performed to select 
of appropriate and effective antifungal therapy, and mon-
itor the development of resistance.
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